Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
ACN$264.57+10.01(+3.93%)Accenture vs. Oracle: Which Technology Stock Is a Better Buy in 2027?12:00:02 PM ETBRK-A$860,178.70+24,048.41(+2.88%)Berkshire Hathaway Buys More Sirius XM, Sending Stock to 52-Week High11:56:00 AM ETNVDA$203.21-3.35(-1.62%)Can NVDA Stock Jump From Here?11:55:23 AM ETPLTR$170.95-4.39(-2.50%)Why Palantir Technologies Stock Dropped Today11:46:23 AM ETTSLA$385.74-12.60(-3.16%)Tesla's Five Year Stock Price Turns Negative11:46:03 AM ETSHOP$152.34+9.63(+6.75%)Cathie Wood Bought $12.5 Million of Shopify as It Tanked11:37:31 AM ETTSLA$385.74-12.60(-3.16%)Musk's Election Bet Backfires on Tesla, and Your Index Fund Owns a Piece of It11:33:41 AM ETINTC$57.67-2.83(-4.68%)Intel Just Delivered Its Strongest Data Center Growth in 15 Years. Its Comeback Is Gaining Momentum11:33:28 AM ETAMD$486.26+2.43(+0.50%)AMD Rallies After Chipmaker "Beat Where It Mattered" in Earnings11:30:19 AM ETWMT$130.50+5.66(+4.53%)Walmart's Dec. 11 Dividend Isn't the Real Reason to Own the Stock11:30:00 AM ETCEG$246.14-17.16(-6.52%)Constellation Energy Earnings Preview: Why I Remain Bullish Headed Into Q311:21:39 AM ETMU$805.40-49.53(-5.79%)Micron, SK Hynix, SanDisk stocks fall: why Dems' Texas win is spooking investors11:19:40 AM ETGOOG$289.17+10.88(+3.91%)Google faces backlash for plan that would turn off Search for schools that restrict AI11:17:22 AM ETUBER$71.74+5.14(+7.72%)Uber: From AV Victim To A Potential Threat To Tesla (Rating Downgrade)11:15:26 AM ETTJX$146.08+8.44(+6.13%)The TJX Companies, Inc. to Report Q3 FY27 Results November 18, 202611:15:00 AM ETDOX$45.24-17.21(-27.56%)Amdocs Stock Has Its Worst Day in 24 Years as T-Mobile Business Is at Risk11:10:00 AM ETBRK-A$860,178.70+24,048.41(+2.88%)Berkshire Hathaway Is Buying More Sirius XM. Here's What It May See11:05:40 AM ETSBUX$108.92+4.16(+3.97%)McDonald's Rises 5% as Earnings Beat Outweighs U.S. Sales Dip; Chipotle Climbs 4%, Starbucks Gains 3%11:04:48 AM ETBNO$60.26-5.89(-8.90%)Physical Oil Just Went From a Bidding War to a Fire Sale11:04:10 AM ETMU$805.40-49.53(-5.79%)Prediction: This Could Be the Best AI Stock You're Not Talking About11:03:56 AM ETMU$805.40-49.53(-5.79%)SanDisk Slides 5%, Micron and Western Digital Fall 3% as Election and Memory Price Worries Weigh11:02:59 AM ETINTC$57.67-2.83(-4.68%)Intel Drops 5%, NVIDIA Retreats 2% After AMD Earnings Beat and Strong 2027 Outlook as Intel Falls 3%; AMD Stock Goes Nowhere11:02:35 AM ETMCD$277.12+14.05(+5.34%)McDonald's says US sales are improving amid tensions with franchisees: ‘We're taking the right steps'10:58:26 AM ETSKHY$144.18-6.69(-4.43%)Got $5,000? Buy These 2 Growth Stocks Powering the AI Memory Boom (Hint: Micron Isn't One of Them)10:55:00 AM ET

IMNM · NASDAQ

Immunome, Inc.

$18.62 -1.71 (-8.41%)

Company overview

Immunome, Inc. is a biopharmaceutical company that discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38, a tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$2.2B
Employees
131
Headquarters
Bothell, PA
Website
immunome.com
CEO
Clay Siegall
Listed
October 2, 2020
P/E
-7.79
Dividend yield
0.00%

Company financials

Revenue
$4M
Gross profit
-$46.7M
Operating income
-$239M
EBITDA
-$233M
Net income
-$225M
EPS
-$2.39
Total assets
$620M
Total debt
$3.7M
Gross margin
-1,161.92%
Net margin
-5,593.85%
Earnings yield
-12.84%

Price chart

15.8619.5523.2426.9230.61
IMNM 1D NASDAQ O19.81H20.43L19.78C20.33+0.74 (+3.78%)Vol1.52M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
IMNMImmunome, Inc. Press release Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026 Business Wire
IMNMImmunome, Inc. Stock news Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know Zacks Investment Research
IMNMImmunome, Inc. Stock news 4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates Zacks Investment Research
IMNMImmunome, Inc. Press release Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference Business Wire
IMNMImmunome, Inc. Stock news Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors Business Wire
IMNMImmunome, Inc. Press release Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026 Business Wire
IMNMImmunome, Inc. Press release Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
IMNMImmunome, Inc. Stock news Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors Business Wire
BRZE Stock news ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session Benzinga
IMNMImmunome, Inc. Press release Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
IMNMImmunome, Inc. Press release Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference Business Wire
IMNMImmunome, Inc. Stock news argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing MarketBeat
IMNMImmunome, Inc. Press release argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis GlobeNewswire
IMNMImmunome, Inc. Stock news Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon Seeking Alpha
IMNMImmunome, Inc. Press release Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update Business Wire
TDC Stock news SpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session Benzinga
IMNMImmunome, Inc. Press release Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors Business Wire
IMNMImmunome, Inc. Stock news What This Immunome Sale Means a Day Before a Big FDA Milestone The Motley Fool
IMNMImmunome, Inc. Stock news Immunome Stock Up 32% in a Month: Here's What You Should Know Zacks Investment Research
IMNMImmunome, Inc. Press release Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors Business Wire
See more
FAQ

Questions about Immunome, Inc.

What does Immunome, Inc. do?
Immunome, Inc. is a biopharmaceutical company that discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38, a tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
What is IMNM's market cap?
Immunome, Inc. (IMNM) is a listed stock with a live quote. The latest market cap on this page is $2.2B.
Where is Immunome, Inc. headquartered?
Immunome, Inc. is headquartered in Bothell, PA.
How do I get IMNM news from the API?
Call GET /v1/news?tickers=IMNM. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does IMNM news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for IMNM, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the IMNM price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs